Amer Zeidan: On behalf of an international panel, we issued a call-for-action to harmonize/unify WHO22 and ICC22 classifications for AML

On behalf of an international panel, we issued a call-for-action to harmonize/unify WHO22 & ICC22 classifications for AML warning about important negative consequences to patient care, trials, drug approvals, & epidemiological research with status quo.

Navigating through classifications of AML & MDS needs a GPS or AI these days. We need more practical & pragmatic classifications that can inform prognosis or/& support evidence-based therapeutic decisions rather than just creating an endless number of pathologic subgroups.

For the article click here

Source: Amer Zeidan / Twitter

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.